Safety of Arnuity (Fluticasone Furoate) in Pregnancy
Arnuity can be safely continued during pregnancy if you were well-controlled on it before conception, though budesonide remains the preferred first-line inhaled corticosteroid due to more extensive human pregnancy data. 1
Key Recommendation
The FDA label for Arnuity states there are "insufficient data" on use in pregnant women, with animal studies showing no fetal structural abnormalities at doses up to 4 times the maximum recommended human dose 1. However, the critical clinical principle is this: maintaining asthma control during pregnancy is more important than theoretical medication risks, as poorly controlled asthma poses documented risks of pre-eclampsia, prematurity, low birth weight, and small-for-gestational-age infants 1.
Evidence-Based Approach
If Already on Arnuity Pre-Pregnancy:
- Continue the medication - The 2005 NAEPP guidelines explicitly state that inhaled corticosteroids other than budesonide "may be continued in patients who were well controlled by these agents prior to pregnancy, especially if it is thought that changing formulations may jeopardize asthma control" 2
- Switching medications risks destabilizing asthma control, which poses greater fetal risk than continuing fluticasone furoate
If Starting New Therapy During Pregnancy:
- Budesonide is the preferred inhaled corticosteroid because it has the most extensive human pregnancy safety data 2
- The 2020 ERS/TSANZ guidelines confirm that "inhaled medications have been used for many years without documentation of adverse effects on the fetus" 3
Class Effect Safety
All inhaled corticosteroids appear to share a favorable safety profile:
- A 2015 UK cohort study of 5,362 pregnancies found no increased risk of major congenital malformations with first-trimester fluticasone propionate exposure compared to other inhaled corticosteroids 4
- The adjusted odds ratio was 1.2 (95% CI 0.7-2.0) for considerable/severe asthma - essentially no difference 4
- While this study examined fluticasone propionate (not furoate), the similar pharmacologic profiles suggest comparable safety
Critical Clinical Pitfall
The greatest danger is undertreating asthma, not the medication itself. Maternal hypoxia from severe exacerbations has well-documented adverse fetal effects 3. The 2020 guidelines emphasize that "the effect of undertreated asthma resulting in a severe exacerbation with maternal hypoxia is well described to have adverse effects on the fetus" 3.
Monitoring Requirements
- Close monitoring throughout pregnancy with medication adjustments as needed to maintain optimal control 1
- The goal is preventing exacerbations that require systemic corticosteroids, which carry higher risks (oral clefts, preeclampsia, reduced birth weight) than inhaled therapy 2, 5
Lactation Considerations
The FDA label notes "no information available" on fluticasone furoate in breast milk, though low concentrations of other inhaled corticosteroids have been detected in human milk 1. The 2020 guidelines classify most inhaled corticosteroids as "compatible" or "probably safe" for breastfeeding 3.